ARTICLE | Clinical News
House dust mites sublingual immunotherapy tablet: Phase II data
May 14, 2012 7:00 AM UTC
The dose-ranging, double-blind, Canadian Phase II VO67.10 trial in 355 adults with house dust mite allergic rhinitis showed that the once-daily 500 IR dose of Stallergenes' house dust mites sublingual...